Effect of dose adjustment on the safety and efficacy of afatinib forEGFRmutation-positive lung adenocarcinoma:post hocanalyses of the randomized LUX-Lung 3 and 6 trials
出版年份 2016 全文链接
标题
Effect of dose adjustment on the safety and efficacy of afatinib forEGFRmutation-positive lung adenocarcinoma:post hocanalyses of the randomized LUX-Lung 3 and 6 trials
作者
关键词
-
出版物
ANNALS OF ONCOLOGY
Volume 27, Issue 11, Pages 2103-2110
出版商
Oxford University Press (OUP)
发表日期
2016-09-07
DOI
10.1093/annonc/mdw322
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
- (2016) Keunchil Park et al. LANCET ONCOLOGY
- First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study
- (2015) Y.-L. Wu et al. ANNALS OF ONCOLOGY
- Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK
- (2015) R. Califano et al. DRUGS
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
- (2015) James Chih-Hsin Yang et al. LANCET ONCOLOGY
- Nutritional Status, Body Surface, and Low Lean Body Mass/Body Mass Index Are Related to Dose Reduction and Severe Gastrointestinal Toxicity Induced by Afatinib in Patients With Non-Small Cell Lung Cancer
- (2015) O. Arrieta et al. ONCOLOGIST
- Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors
- (2014) Matthias Freiwald et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer
- (2014) Sung Hoon Sim et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations
- (2013) Lecia V. Sequist et al. JOURNAL OF CLINICAL ONCOLOGY
- First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
- (2012) Ji-Youn Han et al. JOURNAL OF CLINICAL ONCOLOGY
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations
- (2011) Hironori Satoh et al. Journal of Thoracic Oncology
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
- (2011) Caicun Zhou et al. LANCET ONCOLOGY
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- (2009) Tetsuya Mitsudomi et al. LANCET ONCOLOGY
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- (2009) Tony S. Mok et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started